PAL to Improve Oral Feeding for Infants With Chronic Lung Disease
Trial Summary
What is the purpose of this trial?
The purpose of this study is to investigate the effects of the Pacifier Activated Lullaby (PAL) intervention on the transition to oral feeding for preterm infants with chronic lung disease and respiratory distress syndrome that require non-invasive respiratory support at 34 weeks PMA. This study will utilize a clinical trial design. Participants will be randomized into two groups. One group will receive the PAL intervention, the other group serving as a no contact control. Participants will be matched based on sex, gestational age at birth, and neurologic injury. Infants in the intervention group will receive two PAL sessions a week until successfully transitioned to \<2L of respiratory support and then receive one PAL session within 24 hours of their first oral feeding attempt.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What data supports the effectiveness of the treatment Pacifier Activated Lullaby (PAL) for improving oral feeding in infants with chronic lung disease?
Research shows that using pacifiers and playing lullabies can help premature infants transition to full oral feeding more successfully and improve their sucking ability. Additionally, non-nutritive sucking with a pacifier has been found to positively affect the health and behavior of preterm infants.12345
Is the Pacifier Activated Lullaby (PAL) intervention safe for use in infants?
The Pacifier Activated Lullaby (PAL) intervention has been studied in premature infants and has not shown any significant safety concerns. Pacifier use, in general, is considered safe for infants and is associated with benefits like pain relief and reduced risk of sudden infant death syndrome, though prolonged use may affect breastfeeding and dental health.26789
How is the Pacifier Activated Lullaby (PAL) treatment different from other treatments for infants with chronic lung disease?
The Pacifier Activated Lullaby (PAL) treatment is unique because it uses music to encourage non-nutritive sucking in premature infants, which helps them transition to oral feeding more quickly. This approach is different from other treatments as it combines a pacifier with music reinforcement to improve feeding skills, rather than relying solely on traditional feeding methods.1261011
Research Team
Eligibility Criteria
This trial is for preterm infants with chronic lung disease and respiratory distress syndrome who need non-invasive breathing support and can handle a little bit of sound. They should be born before 33 weeks of pregnancy and enrolled before reaching 35 weeks. Babies with certain bowel issues, on invasive breathing support, in other music therapy studies, or without any respiratory support are not eligible.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Infants in the experimental group receive the PAL intervention 2 times a week until they transition to room air or <2L high flow nasal cannula and begin oral feeding attempts.
Control
Infants in the control group do not receive any music therapy intervention throughout NICU admission.
Follow-up
Participants are monitored for safety and effectiveness after treatment, focusing on the transition to oral feeding and respiratory support.
Treatment Details
Interventions
- Pacifier Activated Lullaby (PAL) intervention (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Missouri-Columbia
Lead Sponsor
Mun Y. Choi
University of Missouri-Columbia
Chief Executive Officer since 2017
PhD in Mechanical and Aerospace Engineering from Princeton University
Richard Barohn
University of Missouri-Columbia
Chief Medical Officer since 2020
MD from the University of Missouri-Columbia School of Medicine
University of Georgia
Collaborator
Dr. Biao He
University of Georgia
Chief Executive Officer
PhD in Veterinary Medicine
Dr. Hank Radziewicz
University of Georgia
Chief Medical Officer
MD from Duke University, MSCR from Emory University